Managing Hypertension During and After Menopause

1. Introduction: The Menopausal Transition and Rising Cardiovascular Risk

Cardiovascular risk in women rises sharply in the decade surrounding menopause, and blood pressure (BP) is central to that shift. For much of adult life, women have a lower prevalence of hypertension than age-matched men; by the seventh decade, this gap closes and reverses. Traditionally attributed solely to chronological ageing, a substantial body of evidence now indicates that the menopausal transition itself - independent of age - contributes meaningfully to this rise in BP and overall cardiovascular risk.

The transition is not a single event but a multi-year process spanning perimenopause (marked by hormonal fluctuation and cycle irregularity) through to established postmenopause (persistent oestrogen deficiency). Blood pressure trajectories differ across this window: some women experience labile, fluctuating readings during perimenopause, while others develop a more gradual, sustained rise in mean BP after the final menstrual period.

For clinicians managing midlife women - particularly those with additional risk factors such as obesity, prior hypertensive pregnancy, or a family history of cardiovascular disease - recognising menopause as a distinct cardiovascular inflection point, rather than a proxy for ageing alone, supports earlier and more targeted intervention.

This article outlines the mechanisms linking menopause to blood pressure change, reviews the current evidence base, and provides practical guidance on assessment and management, including considerations relevant to menopausal hormone therapy (MHT).

2. Mechanisms: How Menopause Alters Blood Pressure Regulation

The decline in ovarian oestrogen production that defines menopause has direct and indirect effects on the systems governing blood pressure. Several interrelated mechanisms are implicated.

Oestrogen Withdrawal and Vascular Tone

Oestrogen supports vascular health through multiple pathways, including upregulation of endothelial nitric oxide synthase (eNOS) and enhanced nitric oxide (NO)-mediated vasodilation. As circulating oestrogen falls, NO bioavailability decreases and endothelium-dependent vasodilation is impaired, producing a shift toward increased vascular tone and peripheral resistance.

RAAS and Sympathetic Activation

Oestrogen deficiency is associated with increased activity of the renin-angiotensin-aldosterone system (RAAS) and heightened sympathetic nervous system tone. Both pathways promote vasoconstriction, sodium retention, and increased plasma volume, compounding the loss of oestrogen-mediated vasodilation and contributing to a measurable rise in mean BP in many women.

Endothelial Dysfunction and Arterial Stiffening

Alongside reduced NO bioavailability, the menopausal transition is associated with increased oxidative stress and low-grade vascular inflammation, accelerating endothelial dysfunction. Over time, this contributes to arterial stiffening, reflected in rising pulse wave velocity and pulse pressure - changes that increase cardiac afterload and are independently associated with adverse cardiovascular outcomes.

Visceral Adiposity and Salt Sensitivity

Menopause is associated with a shift in fat distribution toward visceral adiposity, even in the absence of significant total weight gain. Visceral fat is metabolically active and contributes to insulin resistance, RAAS activation, and increased salt sensitivity of blood pressure - meaning a given dietary sodium load produces a greater BP response than it would premenopausally.

3. Evidence Overview: Menopause and Hypertension Risk

The evidence linking the menopausal transition to blood pressure change draws primarily from large longitudinal cohorts designed to separate the effects of menopause from those of chronological ageing.

Cohort Evidence

The Study of Women's Health Across the Nation (SWAN), a multi-site longitudinal cohort following women through the menopausal transition, has demonstrated that increases in systolic BP and unfavourable lipid changes track more closely with menopausal stage than with age alone, supporting menopause as an independent contributor to cardiovascular risk rather than a simple marker of time passing. Framingham Heart Study data similarly show a steeper rise in hypertension prevalence in women after the median age of menopause compared with the preceding decade.

The Timing Hypothesis and MHT

Evidence from randomised and observational studies of menopausal hormone therapy has given rise to the "timing hypothesis": cardiovascular effects of MHT differ depending on whether therapy is initiated close to menopause onset versus many years later. In women initiating MHT earlier in the transition, vascular effects are generally more favourable or neutral, whereas initiation in older women or those with established atherosclerosis has been associated with less favourable outcomes in some analyses. This distinction is directly relevant to BP management decisions, since MHT formulation, route, and timing all influence its cardiovascular risk profile.

Guideline Positions

The American Heart Association's 2020 scientific statement on the menopause transition and cardiovascular disease risk identifies the menopausal transition as a window of opportunity for cardiovascular risk assessment and early prevention, recommending closer BP surveillance during this period. The 2018 ESC/ESH hypertension guidelines, updated by the 2021 ESH practice guidelines, and NICE guidance on menopause management both support individualised assessment of cardiovascular risk before initiating MHT, with blood pressure control regarded as a prerequisite rather than a contraindication in most cases.

4. Clinical Assessment: Identifying BP Change Across the Transition

Because BP change across menopause can be gradual and its onset overlaps with a life stage in which women are not always in regular contact with primary care, structured assessment is important to avoid missed or delayed diagnosis.

Distinguishing Perimenopausal Lability from Sustained Hypertension

Perimenopausal women may report symptoms - palpitations, flushing, night sweats - that overlap with, and can mask, episodic BP elevation. Where possible, BP should be assessed outside of acute vasomotor episodes, and single elevated readings during a hot flush should not be used in isolation to diagnose hypertension. Serial or out-of-office measurement is preferred to distinguish transient lability from a sustained upward trend.

Role of Home and Ambulatory Monitoring

Home blood pressure monitoring (HBPM) is particularly well suited to this population, allowing readings to be captured over time without requiring additional clinic visits, and enabling correlation between BP readings and symptom diaries where vasomotor symptoms are prominent. Ambulatory blood pressure monitoring (ABPM) may be used where masked hypertension or nocturnal BP changes are suspected, or where MHT initiation is being considered in a woman with borderline office readings.

Baseline Assessment Before MHT Initiation

Current guidance supports BP measurement prior to initiating MHT, with hypertension treated and controlled rather than considered an absolute contraindication in most women. Where BP is elevated or labile at baseline, a short period of home monitoring can clarify the picture before a treatment decision is made, and BP should be rechecked shortly after MHT initiation given the potential, formulation-dependent effects of exogenous hormones on BP.

5. Management Strategies: Protecting Cardiovascular Health Through the Transition

Management spans MHT-related decision-making, pharmacological treatment of hypertension where indicated, and lifestyle intervention, with the shared goal of limiting cumulative cardiovascular risk across the transition.

MHT Considerations

Where MHT is being considered, route and formulation are relevant to blood pressure effects: transdermal oestrogen avoids first-pass hepatic metabolism and is generally associated with a more neutral BP profile than oral formulations, which can increase hepatic angiotensinogen production. In women with existing hypertension that is adequately controlled, MHT is not typically contraindicated, but shared decision-making should account for overall cardiovascular risk, formulation choice, and the timing hypothesis described above.

Pharmacological Treatment of Hypertension

For antihypertensive agent selection in perimenopausal and postmenopausal women, clinicians are referred to current ESC/ESH and ACC/AHA hypertension guidelines. Drug-drug interaction potential with MHT, and the presence of menopause-associated metabolic changes such as dyslipidaemia or insulin resistance, may inform agent choice in individual patients.

Lifestyle Interventions

• Sodium restriction: given the increased salt sensitivity associated with menopause, dietary sodium reduction toward the ESC/ESH-recommended target of under 5g/day may have a proportionally greater BP benefit in this population.

• Physical activity: regular aerobic and resistance exercise supports blood pressure control and helps offset the shift toward visceral adiposity; at least 150 minutes of moderate-intensity activity per week is recommended.

• Weight management: given the tendency toward visceral fat redistribution at menopause independent of total weight change, waist circumference is a useful adjunct to BMI in risk assessment.

• Sleep and vasomotor symptom management: poor sleep and frequent night sweats are associated with adverse cardiometabolic profiles; addressing sleep disruption, including through evidence-based management of vasomotor symptoms, may have downstream BP benefits.

• Alcohol moderation: limiting intake to under 14 units per week, consistent with general hypertension guidance.

Monitoring Cadence

• Perimenopause: opportunistic BP measurement at routine contacts, with home monitoring considered where symptoms or risk factors warrant closer surveillance.

• MHT initiation: baseline BP assessment, with a follow-up check within the first few months of starting or changing therapy.

• Postmenopause with elevated or borderline BP: structured home monitoring protocol (morning and evening duplicate readings over 7 days) at each review, or annually in lower-risk women.

• Annual review: reassess overall cardiovascular risk profile, including lipids and glycaemic status, alongside BP trend.

6. Conclusion

The menopausal transition represents a distinct and clinically actionable window for cardiovascular risk assessment, with blood pressure change occurring earlier and more independently of chronological ageing than has traditionally been assumed. Mechanistic and cohort evidence together support proactive BP surveillance from perimenopause onward, and BP status should directly inform - without automatically precluding - decisions around menopausal hormone therapy.

Key practice points for clinicians:

• Treat the menopausal transition as a cardiovascular risk assessment opportunity, not solely a reproductive health milestone.

• Use out-of-office measurement to distinguish perimenopausal BP lability from sustained postmenopausal hypertension, particularly where vasomotor symptoms are prominent.

• Assess and, where necessary, control BP before initiating MHT, and recheck shortly after starting or changing therapy, with route/formulation considered as part of the risk discussion.

• Address salt sensitivity, visceral adiposity, and sleep disruption as menopause-specific contributors to BP change, alongside standard lifestyle advice.

Encouraging women to conduct regular, structured home BP monitoring through the menopausal transition is not merely a matter of convenience - it supports earlier detection of emerging hypertension and provides the longitudinal data needed to inform MHT decisions with confidence. This is particularly valuable in a life stage where BP change can otherwise go undetected between infrequent clinic visits.

Omron Healthcare offers a range of clinically validated home blood pressure monitors designed to support this approach, enabling healthcare professionals to integrate accurate, longitudinal BP data into the care of women across the menopausal transition. OMRON Academy has also created a free, CPD-accredited short course on women's cardiovascular health, available at academy.omron-healthcare.com.

Approval code: OHEAPP-1202